Meta-analysis of Intravitreal Injection of Anti-vascular Endothelial Growth Factors for Diabetic Macular Edema
10.3341/jkos.2019.60.2.144
- Author:
Hajin TCHOE
1
;
Sang Jin SHIN
;
Jae Kyung SUH
;
Songhee CHO
;
Jangmi YANG
;
Min Joo KANG
;
Donghyun JEE
Author Information
1. Office of Economic Evaluation Research, National Evidence Based Healthcare Collaborating Agency, Seoul, Korea.
- Publication Type:Meta-Analysis
- Keywords:
Aflibercept;
Anti-vascular endothelial growth factor;
Diabetic macular edema;
Ranibizumab
- MeSH:
Bevacizumab;
Dexamethasone;
Diabetic Retinopathy;
Endothelial Growth Factors;
Humans;
Intravitreal Injections;
Macular Edema;
Ranibizumab;
Visual Acuity
- From:Journal of the Korean Ophthalmological Society
2019;60(2):144-151
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: Intravitreal aflibercept, ranibizumab, bevacizumab, and dexamethasone are the most widely used drugs in the treatment of diabetic macular edema (DME). The aim of this study was to compare the efficacy and safety of anti-vascular endothelial growth factors and dexamethasone for the treatment of DME. METHODS: There were nine previous systematic reviews on this topic; we updated these high-quality reviews. Seven studies were added to two studies following a literature search. Efficacy outcomes were 1) average improvement in visual acuity, 2) proportion of patients who experienced an improvement in vision (an increase in best-corrected visual acuity (BCVA) of ≥ 15 in the Early Treatment Diabetic Retinopathy Study [ETDRS]), and 3) proportion of patients who experienced worsening vision (a decrease in BCVA of ≥ 15 in the ETDRS). Safety outcomes included systemic adverse events and ocular-related adverse events. RESULTS: The mean difference in the BCVA for ranibizumab versus bevacizumab treatment was 0.16 (95% confidence interval [CI]: −0.02, 0.34), and that for ranibizumab versus aflibercept was −0.08 (95% CI: −0.26, 0.10). The mean difference in the change of BCVA for aflibercept versus ranibizumab was −0.20 (95% CI: −0.40, −0.01), and that for aflibercept versus bevacizumab was −0.34 (95% CI: −0.53, −0.14). Other efficacy outcomes showed similar trends, and there was no significant difference between treatments. There was also no significant difference in both systemic and ocular adverse events rates between the treatments. CONCLUSIONS: In DME patients, the efficacy of aflibercept was found to be higher with respect to BCVA changes compared with ranibizumab or bevacizumab. However, there were no significant difference in terms of visual acuity improvement or visual acuity of more than 15 letters, nor in terms of anti-vascular endothelial growth factors (as a safety outcome).
